Serum levels of GFAP and EGFR in primary and recurrent high-grade gliomas: correlation to tumor volume, molecular markers, and progression-free survival

What do we know about IDH1/2 mutations so far, and how do we use it?

(2013) Craig Horbinski   ACTA NEUROPATHOLOGICA

Blood-based biomarkers for malignant gliomas

(2013) Matthias Holdhoff et al.   JOURNAL OF NEURO-ONCOLOGY

Epidermal growth factor receptor

(2012) Monika E. Hegi et al.   CURRENT OPINION IN NEUROLOGY

Pre- and post-operative plasma glial fibrillary acidic protein levels in patients with newly diagnosed gliomas

(2012) Hatim Husain et al.   JOURNAL OF NEURO-ONCOLOGY

Exploratory investigation of eight circulating plasma markers in brain tumor patients

(2012) Aysegul Ilhan-Mutlu et al.   NEUROSURGICAL REVIEW

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

(2012) Marco Gerlinger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pseudoprogression and Pseudoresponse: Imaging Challenges in the Assessment of Posttreatment Glioma

(2011) L.C. Hygino da Cruz et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer

(2011) A Ålgars et al.   BRITISH JOURNAL OF CANCER

The hypermethylation of the O6-methylguanine-DNA methyltransferase gene promoter in gliomas-correlation with array comparative genome hybridization results and IDH1 mutation

(2011) Katja Tuononen et al.   GENES CHROMOSOMES & CANCER

Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma

(2010) Rabab Gaafar et al.   LUNG CANCER

GFAP and S100B are biomarkers of traumatic brain injury: An observational cohort study

(2010) P. E. Vos et al.   NEUROLOGY

Monoclonal antibody specific for IDH1 R132H mutation

(2009) David Capper et al.   ACTA NEUROPATHOLOGICA